Recent Finacing
Recent Raise
SixPeaks Bio develops conjugated activin IIA/B dual-specific antibodies linked to GLP-1 and other incretins, aiming to enhance GLP-1–mediated weight loss while preserving muscle, validated in preclinical models.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at SixPeaks Bio.
